Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AF Symposium 26: ADVENT LTO: Long-Term PFA Outcomes and AF Progression
Author(s): Vivek Reddy Added: 4 weeks ago
AF Symposium 2026 - Dr Vivek Reddy (Icahn School of Medicine at Mount Sinai, New York, NY, US) joins us to discuss findings from the ADVENT LTO study, evaluating long-term outcomes and atrial fibrillation progression in patients who received ablation with the FARAPULSE Pulsed Field Ablation System compared to thermal ablation.The study tracked AF progression patterns, arrhythmia recurrence rates,… View more

Electrophysiology & Arrhythmia
Outcomes of Ticagrelor Following Fibrinolysis: Australian Data
Author(s): Rohullah Sultani , Jasmine Chan , Timothy Abrahams , et al Added: 1 month ago

Anticoagulation

MI/ACS
Real-World Data for CV and Renal Outcomes in DKD
Author(s): David Wheeler Added: 9 months ago
ERA 2025 - Prof David Wheeler (University College London, London, UK) joins us to discuss outcomes from real-world data investigating cardiovascular and renal outcomes in patients with DKD.Interview Questions:1. How do real-world cardiovascular and renal outcomes compare to clinical trial results, and which data sources are giving us the best insights into DKD outcomes?2. What's the biggest gap… View more

Cardiovascular Renal Metabolic
Pregnancy Outcomes in ACHD Patients in Indonesia
Author(s): Dyah Wulan Anggrahini , Detty Siti Nurdiati , Anggoro Budi Hartopo , et al Added: 4 months ago

Inherited and Congenital Cardiac Conditions

Prevention & Chronic Conditions
AHA 24: New Insights from CLEAR OUTCOMES
Author(s): Marc P Bonaca Added: 1 year ago
AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD).Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).CLEAR OUTCOMES is a double-blind,… View more

Vascular Disease and Surgery

Prevention & Chronic Conditions
ESC 25: STRIDE: Outcomes by Sex
Author(s): Subodh Verma Added: 6 months ago
ESC Congress 2025 - New findings from STRIDE further demonstrate effectiveness of semaglutide in improving functional outcomes in PAD.Dr Subodh Verma joins us to discuss new findings from the STRIDE study, which investigated semaglutide 1.0mg in individuals with peripheral artery disease (PAD). 792 participants were enrolled in the trial, 24.6% of which were female, and 75.4% male.Findings showed… View more

Prevention & Chronic Conditions

Vascular Disease and Surgery
TCT 25: Real-World EVOQUE Outcomes from TVT Registry
Author(s): Raj Makkar Added: 4 months ago
TCT 25 - Dr Raj Makkar (Cedars-Sinai Medical Center, US) joins us to discuss the findings on the EVOQUE Valve (Edwards Lifesciences) drawing from data in the STS/ACC Transcatheter Valve Therapy Registry.The study evaluated procedural success rates, in-hospital complications, and 30-day clinical outcomes in patients undergoing transcatheter tricuspid valve replacement for severe tricuspid… View more

Intervention
ADA 24: FLOW Trial: Kidney Outcomes in Patients Treated with Semaglutide
Author(s): Vlado Perkovic Added: 1 year ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Stanford TAAD: Epidemiology and Surgical Outcomes
Author(s): Shun Watanabe Added: 1 year ago

Vascular Disease and Surgery

Prevention & Chronic Conditions
EuroPCR 25: The TRINITY Trial
Author(s): Thomas Modine Added: 9 months ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement… View more

Heart Failure

Intervention